Skip to main content
Signal8

ALTERITY THERAPEUTICS LTD (ATHE)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Alterity Therapeutics Limited logo

Alterity Therapeutics Limited

NASDAQ:ATHEHealthcare
+0.00%$1.96
CLOSED
AH$1.96+0.00%vs close
Mkt Cap$37.42M
EV-
Float16.12M
O/S19.09M
VOL13K sh
$ Vol$26K
RVOL0.06×
Inst Own2.0%
SI0.1%
Net Cash/Sh-
Dilution
Alterity Therapeutics Limited logoNASDAQ:ATHEClosed$1.96+0.00%
Historical Data
DateOpenHighLowCloseVolume
Nov 16, 20261.962.051.891.9613,410
Nov 13, 20262.042.141.701.96109,693
Nov 12, 20262.282.282.042.1071,750
Nov 11, 20262.252.362.252.3119,335
Nov 10, 20262.462.502.292.3216,190
Nov 9, 20262.432.542.382.439,937
Nov 6, 20262.352.452.352.4313,430
Nov 5, 20262.352.582.172.2240,341
Nov 4, 20262.472.652.372.44131,498
Nov 3, 20262.103.292.102.474,037,140
Nov 2, 20262.172.232.092.096,062
Oct 30, 20262.232.242.112.169,062
Oct 29, 20262.252.252.162.233,790
Oct 28, 20262.202.292.152.1723,310
Oct 27, 20262.142.242.022.143,527
Oct 26, 20262.082.362.012.087,915
Oct 23, 20262.122.432.042.0926,791
Oct 22, 20262.262.292.092.1553,307
Oct 21, 20262.442.622.302.3956,523
Oct 20, 20262.412.512.372.3717,733
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$10.00+410.2%
Low $10High $10
Ratings Distribution
BUY
4
HOLD
4
SELL
0
TOTAL8
Insider Trades
InsiderTypeShares
Marks Peter Ashley profile photoMarks Peter AshleyPurchase47.6K
Marks Peter Ashley profile photoMarks Peter AshleyPurchase47.6K
Stamler David Allen profile photoStamler David AllenPurchase47.6K
Gozlan Lawrence Bernard profile photoGozlan Lawrence BernardGrant/Award1.00M
Babarczy Julian Michael profile photoBabarczy Julian MichaelGrant/Award2.00M
Shareholders
2.0%
Institutional
(23)
61.2%
Insiderⓘ
(1)
0.0%
5%+ Owners
(0)
36.7%
Unattributed (incl. retail)ⓘ
Institutional2.0%
Insider61.2%
Unattributed (incl. retail)36.7%
Sources: 13F, Form 4, 13D/13GO/S: 19.1M · as of 30 Sep 2026 · SEC filings
Insiders & Institutional Holders
About

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases.

Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease.

The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.

Key Metrics
Market Cap$37.42M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership2.03%

based on 19.09M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryAUAU
IPO DateSep 29, 2003
Shares Outstanding19.09M
Authorized Shares
Float16.12M
SEC Float (non-affiliate)18.90M
52-Week Range
$1.70$5.89
$1.96(6th percentile)
Volume
Average Daily Volume223.46K
13.41K today vs 223.46K avg(-94%)

30d Avg

223.46K

60d Avg

127.38K

90d Avg

90.61K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of ATHE as of Jun 30, 2026 records 1 outstanding warrant series, from SEC filings. 1 insider reported 1 open-market purchase of ATHE stock on Form 4 in the 90 days to Nov 17, 2026. Alterity Therapeutics Ltd (NASDAQ: ATHE) traded at $1.96 on Nov 16, 2026, unchanged from the previous close of $1.96. 52-week range: $1.70 to $5.89. The company is in the Healthcare sector (Biotechnology).